Version 1
: Received: 12 July 2022 / Approved: 14 July 2022 / Online: 14 July 2022 (12:22:21 CEST)
How to cite:
Degli Antoni, M.; Giagulli, C.; Messali, S.; Amadasi, S.; Caccuri, F.; Castelli, F.; Caruso, A.; Quiros-Roldan, E. Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 Infection. Preprints2022, 2022070223. https://doi.org/10.20944/preprints202207.0223.v1
Degli Antoni, M.; Giagulli, C.; Messali, S.; Amadasi, S.; Caccuri, F.; Castelli, F.; Caruso, A.; Quiros-Roldan, E. Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 Infection. Preprints 2022, 2022070223. https://doi.org/10.20944/preprints202207.0223.v1
Degli Antoni, M.; Giagulli, C.; Messali, S.; Amadasi, S.; Caccuri, F.; Castelli, F.; Caruso, A.; Quiros-Roldan, E. Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 Infection. Preprints2022, 2022070223. https://doi.org/10.20944/preprints202207.0223.v1
APA Style
Degli Antoni, M., Giagulli, C., Messali, S., Amadasi, S., Caccuri, F., Castelli, F., Caruso, A., & Quiros-Roldan, E. (2022). Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 Infection. Preprints. https://doi.org/10.20944/preprints202207.0223.v1
Chicago/Turabian Style
Degli Antoni, M., Arnaldo Caruso and Eugenia Quiros-Roldan. 2022 "Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 Infection" Preprints. https://doi.org/10.20944/preprints202207.0223.v1
Abstract
Coronavirus disease 19 (COVID-19) continues to spread worldwide as a severe pandemic. The Omicron BA.2 became the predominant variant and the protagonist of the ongoing surge. As the virus continues to mutate, using of approved drugs or developing new therapeutic or prophylactic therapies against COVID-19 could be more complex. Sotrovimab is a monoclonal antibody (mAb) targeting the conserved epitope on the spike protein receptor; the most recent studies observed that it has substantially decreased in vitro activity against the Omicron BA.2 subvariant, but real-life data are still scarce. We describe the outcome of a case series of outpatients with BA.1 or BA.2 infection treated with sotrovimab. We conducted a retrospective observational study including all non-hospitalized adult patients treated with sotrovimab, for which a Sanger sequencing of SARS-CoV-2 was performed within a regional genomic surveillance program. Eleven (50%) patients with BA.1 infection and eleven (50%) with BA.2 infection were considered. Most patients were immunocompromised. During the follow-up period, no patient died and only one with BA.1 infection was hospitalized for severe COVID-19 pneumonia onset. One month after treatment, 90.9% of patients were completely asymptomatic in each group. We demonstrated that patients carrying the BA.2 variant treated with sotrovimab did not evolve to severe COVID-19, showing a similar outcome to BA.1 infected patients. Further studies are needed to prove that vaccination or the presumably high doses of mAbs used can protect this group of patients at high risk of progression.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
,
,
*
